Schizophrenia adjunctive medications

Despite the advent of the atypical antipsychotic agents, efforts continue to identify other adjunctive medications that may improve response to standard treatments. In this context, we note that there is no consistent evidence that BZD monotherapy benefits schizophrenia. Another strategy, however, is the addition of BZDs to an antipsychotic regimen. This pharmacological approach is partially based on the evidence that GABA, which is facilitated by BZDs, inhibits certain dopamine tracts and that these medications may attenuate the dopamine system via a different route ( 339, 340, 341 and 342). 

TABLE 7.2 Selective Adjunctive Medications in the Treatment of Schizophrenia... 

---